EC Number   |
General Information |
Reference |
|---|
   1.4.3.13 | drug target |
the enzyme is a promising therapeutic target for the progression of cancer and fibrosis |
764829 |
| 1.4.3.13 | evolution |
the protein is very well conserved throughout the course of evolution |
765178 |
| 1.4.3.13 | malfunction |
association between enzyme polymorphisms and oral submucous fibrosis in older male areca chewers |
699715 |
| 1.4.3.13 | malfunction |
enzyme inhibition stops early mechanical development of tendon constructs and leads to irregularly shaped collagen fibrils |
742874 |
| 1.4.3.13 | malfunction |
excess collagen deposition in ovarian stroma in polycystic ovary syndrome involves increased enzyme activity due to stimulation by advenced glycation end products |
699125 |
| 1.4.3.13 | malfunction |
inhibition of lysyl oxidase activity stabilizes oncogenic stress-induced senescence, delays tumorigenesis, and increases survival |
742237 |
| 1.4.3.13 | malfunction |
reduced enzyme expression is involved in the vitreous of proliferative diabetic retinopathy, PDR, and rhegmatogenous retinal detachment, RRD |
698383 |
| 1.4.3.13 | malfunction |
the enzyme regulates collagen cross-linking, which is increased in heart failure patients compared with healthy hearts. Enzyme overexpression is associated with enhanced collagen cross-linking in the failing human heart. Ability of torasemide to correct both lysyl oxidase overexpression and enhanced collagen cross-linking |
698212 |
| 1.4.3.13 | metabolism |
by deacetylating and deacetyliminating Stat3 on multiple acetyl-lysine sites in nuclei, the enzyme regulates Stat3 dimerization and transcriptional activity. Furthermore, CD4+ T cell differentiation in inflammatory responses is regulated by the enzyme-Stat3 signaling pathway |
743281 |
| 1.4.3.13 | metabolism |
co-overexpression of specific protein 1 (SP1) and LOXL2 significantly correlates with poor prognosis in patients with pancreatic cancer |
765826 |
